Kyverna Therapeutics, Inc.
KYTX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001994702
No open-market purchases or sales by Kyverna Therapeutics, Inc. insiders were filed in the last 90 days; 120 institutions reported holding it in 13F filings for Q2 2026, worth $335.1M in total; no superinvestor holds it.
13F holders, Q2 2026
Institutional positions in Kyverna Therapeutics, Inc. as of Jun 30, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 120
- +10 vs. Q1 2026
- Shares held
- 37.6M
- +2.78M (+8.0%) vs. Q1 2026
- Total value
- $335.1M
- +$34.5M (+11.5%) vs. Q1 2026
- New holders
- 31
- 36 more added
- Sold out
- 21
- 28 more reduced
1 institution that held it in Q1 2026 haven't filed for Q2 2026 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q1 2026: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting KYTX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 120 | $335.1M |
| Q1 2026 | 111 | $300.5M |
| Q4 2025 | 99 | $320.8M |
| Q3 2025 | 75 | $136.1M |
| Q2 2025 | 79 | $71.2M |
| Q1 2025 | 87 | $49.8M |
| Q4 2024 | 88 | $108.0M |
| Q3 2024 | 94 | $138.3M |
| Q2 2024 | 88 | $239.7M |
| Q1 2024 | 90 | $762.3M |
| Q4 2023 | 0 | $0 |
| Q3 2023 | 0 | $0 |
| Q2 2023 | 0 | $0 |
| Q1 2023 | 0 | $0 |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q2 2026
Shares, value and share of portfolio for each institution holding Kyverna Therapeutics, Inc.; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| UBS Group AG | 365,574 | $3.26M | 0.00% | −84,176−18.7% | Reduced |
| Wells Fargo & Company | 373,009 | $3.32M | 0.00% | +258,610+226.1% | Added |
| D. E. Shaw & Co., Inc. | 469,346 | $4.18M | 0.00% | −252,235−35.0% | Reduced |
| Adage Capital Partners GP, L.L.C. | 500,000 | $4.46M | 0.01% | 00.0% | Unchanged |
| MBB Public Markets I LLC | 614,477 | $5.47M | 0.59% | 00.0% | Unchanged |
| Millennium Management LLC | 639,780 | $5.70M | 0.00% | −365,728−36.4% | Reduced |
| Woodline Partners LP | 845,325 | $7.53M | 0.02% | 00.0% | Unchanged |
| Propel Bio Management, LLC | 883,198 | $7.87M | 4.12% | +238,777+37.1% | Added |
| State Street Corp | 982,233 | $8.75M | 0.00% | +843,933+610.2% | Added |
| Morgan Stanley | 982,307 | $8.75M | 0.00% | +5,018+0.5% | Added |
| Insight Holdings Group, LLC | 989,054 | $8.81M | 0.67% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 1,049,430 | $9.35M | 0.00% | +625,604+147.6% | Added |
| Price T Rowe Associates Inc | 1,186,023 | $10.6M | 0.00% | −369,264−23.7% | Reduced |
| Vanguard Capital Management LLC | 1,897,451 | $16.9M | 0.00% | +114,109+6.4% | Added |
| Deerfield Management Company, L.P. (Series C) | 2,000,000 | $17.8M | 0.19% | 00.0% | Unchanged |
| AIGH Capital Management LLC | 2,795,797 | $24.9M | 2.26% | +795,797+39.8% | Added |
| Bain Capital Life Sciences Investors, LLC | 2,885,000 | $25.7M | 1.53% | −225,000−7.2% | Reduced |
| BlackRock, Inc. | 3,134,807 | $27.9M | 0.00% | +2,257,729+257.4% | Added |
| Gilead Sciences, Inc. | 4,126,119 | $36.8M | 2.23% | 00.0% | Unchanged |
| GordonMD Global Investments LP | 4,244,818 | $37.8M | 20.76% | 00.0% | Unchanged |
| Marshall Wace, LLP | 0 | $0 | 0.00% | −605,512−100.0% | Sold out |
| Point72 Asset Management, L.P. | 0 | $0 | 0.00% | −222,929−100.0% | Sold out |
| 683 Capital Management, LLC | 0 | $0 | 0.00% | −85,000−100.0% | Sold out |
| Hudson Bay Capital Management LP | 0 | $0 | 0.00% | −71,059−100.0% | Sold out |
| Voya Investment Management LLC | 0 | $0 | 0.00% | −44,045−100.0% | Sold out |
| Peapod Lane Capital LLC | 0 | $0 | 0.00% | −40,404−100.0% | Sold out |
| Quadrature Capital Ltd | 0 | $0 | 0.00% | −38,411−100.0% | Sold out |
| Mangrove Partners | 0 | $0 | 0.00% | −27,014−100.0% | Sold out |
| Jefferies Financial Group Inc. | 0 | $0 | 0.00% | −23,920−100.0% | Sold out |
| ADAR1 Capital Management, LLC | 0 | $0 | 0.00% | −22,428−100.0% | Sold out |
| Schonfeld Strategic Advisors LLC | 0 | $0 | 0.00% | −20,154−100.0% | Sold out |
| Jacobs Levy Equity Management, Inc | 0 | $0 | 0.00% | −16,599−100.0% | Sold out |
| Gsa Capital Partners LLP | 0 | $0 | 0.00% | −16,161−100.0% | Sold out |
| Raymond James Financial Inc | 0 | $0 | 0.00% | −16,082−100.0% | Sold out |
| Diametric Capital, LP | 0 | $0 | 0.00% | −16,067−100.0% | Sold out |
| Omers Administration Corp | 0 | $0 | 0.00% | −14,800−100.0% | Sold out |
| Graham Capital Management, L.P. | 0 | $0 | 0.00% | −11,965−100.0% | Sold out |
| Fox Run Management, L.L.C. | 0 | $0 | 0.00% | −11,089−100.0% | Sold out |
| Simplex Trading, LLC | 0 | $0 | 0.00% | −3,998−100.0% | Sold out |
| Fortitude Family Office, LLC | 0 | $0 | 0.00% | −126−100.0% | Sold out |
| Advisory Services Network, LLC | 0 | $0 | 0.00% | −86−100.0% | Sold out |
| CWM, LLC | – | – | – | – | Not filed |